Peer-Reviewed Study Helps INMED PHARMACEUTIC (OTCMKTS:IMLFF)’s Cause


It been quite a while since we touched base with INMED PHARMACEUTIC (OTCMKTS:IMLFF) here on Street Register, and with some recent favorable news coming to light, the stock’s price action and volume has been picking up in the month of March.


Like many cannabis related stocks, IMLFF began 2018 with a bang, only to be hit by difficulty over the first couple of months of the year. In the case of IMLFF it has regained roughly half of the ground it lost, and has been trading favorably in recent sessions on the heels of some validation from an outside source.


INMED PHARMACEUTIC (OTCMKTS:IMLFF), which develops novel, cannabinoid-based drug therapies, announced today the publication of a peer-reviewed article in ‘Drug Delivery and Translational Research’.


The article, titled “A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery”, presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed’s Chief Scientific Officer.


In October, 2017, InMed originally announced completion of this study.  These proprietary data support what the Company believes to be a first-in-class nanoparticle-hydrogel formulation for cannabinoid delivery to the eye, resulting in enhanced drug uptake via the cornea and lens.  The patent family for this discovery is currently at the provisional stage and will be converted to a PCT filing during 2018.


“We are highly encouraged by the findings from our discovery, and are now pleased to see our research receiving acceptance from a key peer-reviewed journal”, said Dr. Hossain.  “These study results demonstrate significant delivery of cannabinoids to the eye via transcorneal penetration, resulting in a 300% increase versus a control formulation.  Beyond cannabinoid delivery, we believe our nanoparticle-hydrogel composite may be beneficial for a number of other ophthalmic pharmaceutical products requiring enhanced transport into the eye.”


In these studies, the investigators successfully validated the efficient transport of the formulated product in whole-eye experiments.  The work seamlessly combined product design, synthetic biology, polymer rheology, and analysis of mass transport within ocular tissue. The hydrogel was formulated as a composite of hyaluronic acid (HA) and methylcellulose (MC).  Both polymers are biocompatible and highly muco-adhesive, making them ideal candidates for an ocular formulation.  The amphiphilic nanoparticles were composed of a block copolymer composed of poly-ethylene oxide (PEO) and poly-lactic acid (PLA), designed to facilitate enhanced cannabinoid drug delivery into the eye via the cornea. For this study, the non-psychoactive cannabinoid cannabigerolic acid (CBGA) was biosynthesized using InMed’s proprietary E. coli-based manufacturing approach.  Results from the experiment verified the performance of a stimulus-responsive switching between thixotropy (thinning of the gel upon a shearing force, such as blinking) and temperature-dependent rheopexy (reforming as a gel after blinking), resulting in a thin, uniform gel-like lens that holds the drug in place to allow for transcorneal transport.  Envisioned as a once-per-day (at bedtime) administration, this formulation is designed to address many of the issues associated with current glaucoma medications.


Eric A. Adams, the Company’s President and CEO, added “While glaucoma is certainly a blockbuster opportunity, we believe that our innovations offer solutions beyond this single indication. This research validates InMed’s first-in-class technology, which integrates our proprietary drug-disease targeting platform, highly efficient biosynthesis process of multiple cannabinoid compounds, and delivery of therapeutic products designed to treat multiple diseases with high unmet medical needs.” (Source: PR Newswire)


With such strong validation to the work being done at IMLFF, we are definitely going to want to remain focused on this story and follow along closely going forward. We’ll stay up on any further developments with IMLFF and pass them along to you! Stay locked on and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!



  Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in IMLFF stock, short or long.